| Literature DB >> 33523955 |
Shahad K Alsaiari1, Somayah S Qutub1, Shichao Sun2,3, Walaa Baslyman1, Mansour Aldehaiman4, Mram Alyami1, Abdulaziz Almalik5, Rabih Halwani6, Jasmeen Merzaban4, Zhengwei Mao5,6, Niveen M Khashab7.
Abstract
The major impediments to the implementation of cancer immunotherapies are the sustained immune effect and the targeted delivery of these therapeutics, as they have life-threatening adverse effects. In this work, biomimetic metal-organic frameworks [zeolitic imidazolate frameworks (ZIFs)] are used for the controlled delivery of nivolumab (NV), a monoclonal antibody checkpoint inhibitor that was U.S. Food and Drug Administration-approved back in 2014. The sustained release behavior of NV-ZIF has shown a higher efficacy than the naked NV to activate T cells in hematological malignancies. The system was further modified by coating NV-ZIF with cancer cell membrane to enable tumor-specific targeted delivery while treating solid tumors. We envisage that such a biocompatible and biodegradable immunotherapeutic delivery system may promote the development and the translation of hybrid superstructures into smart and personalized delivery platforms.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33523955 DOI： 10.1126/sciadv.abe7174
Source DB: PubMed Journal: Sci Adv ISSN： 2375-2548 Impact factor: 14.136